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There is substantial evidence that a bioenergetic defect may play a role in the pathogenesis of Huntington's Disease (HD). A potential therapy
for remediating defective energy metabolism is the mitochondrial cofactor, coenzyme Q10 (CoQ10). We have reported that CoQ10 is
neuroprotective in the R6/2 transgenic mouse model of HD. Based upon the encouraging results of the CARE-HD trial and recent evidence that
high-dose CoQ10 slows the progressive functional decline in Parkinson's disease, we performed a dose ranging study administering high levels of
CoQ10 from two commercial sources in R6/2 mice to determine enhanced efficacy. High dose CoQ10 significantly extended survival in R6/2 mice,
the degree of which was dose- and source-dependent. CoQ10 resulted in a marked improvement in motor performance and grip strength, with a
reduction in weight loss, brain atrophy, and huntingtin inclusions in treated R6/2 mice. Brain levels of CoQ10 and CoQ9 were significantly lower in
R6/2 mice, in comparison to wild type littermate control mice. Oral administration of CoQ10 elevated CoQ10 plasma levels and significantly
increased brain levels of CoQ9, CoQ10, and ATP in R6/2 mice, while reducing 8-hydroxy-2-deoxyguanosine concentrations, a marker of oxidative
damage. We demonstrate that high-dose administration of CoQ10 exerts a greater therapeutic benefit in a dose dependent manner in R6/2 mice than
previously reported and suggest that clinical trials using high dose CoQ10 in HD patients are warranted.
© 2006 Elsevier B.V. All rights reserved.Keywords: Huntington's disease; Coenzyme Q10; R6/2 transgenic mice; Therapy; ATP; 8-hydroxy-2-deoxyguanosine; Biomarkers1. Introduction
Huntington's disease (HD) is a progressive and fatal
neurological disorder caused by an expanded CAG repeat in
the gene coding for the protein huntingtin. Despite great
progress, a direct causative pathway from the HD gene mutation⁎ Corresponding author. Edith Nourse Rogers Veterans Administration
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doi:10.1016/j.bbadis.2006.03.004to neuronal dysfunction and death has not yet been established.
It has been postulated, however, that the abnormal aggregation
of the mutant huntingtin protein may cause toxic effects in
neurons, leading to a cascade of pathogenic mechanisms. There
is considerable evidence that a secondary consequence of the
gene defect may be impaired energy metabolism via mitochon-
drial dysfunction [1]. Indeed, N-terminal huntingtin fragments
may directly impair mitochondrial function, leading to
increased oxidative damage, as mitochondria are a major source
of free radicals in the cell [1]. Bioenergetic dysfunction,
therefore, may play a role in cell death in HD. No clinically
proven treatment for HD currently exists and, as such, therapy
that buffers intracellular energy levels and reduces oxidative
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mental evidence in animal models of HD suggests that such a
strategy may be a fruitful avenue in the treatment of HD patients
[2–5].
One such compound is coenzyme Q10 (CoQ10), an important
cofactor in the electron transport chain that also acts as an
antioxidant. Although experimental evidence shows that CoQ10
is efficacious in animal models of HD and has potential as a
therapeutic in HD patients [3,6], it remains unclear whether
optimal CoQ10 dosing has been determined. It may well be that
higher doses of CoQ10 are necessary to significantly slow the
disease process in HD patients. A double-blind, randomized,
controlled study trial in Parkinson's disease patients, using
CoQ10 at 1200 mg/day, slowed the rate of deterioration in the
UPDRS score [7]. Follow up studies in both Parkinson's disease
and amyotrophic lateral sclerosis patients have demonstrated
safe and tolerable doses up to 3000 mg/day [8,9]. While this
evidence suggests that higher doses of CoQ10 may provide
greater efficacy in HD patients, there are significant differences
amongst commercial preparations, each with its own bioavail-
ability characteristics [10,11].
Recent findings suggest that the R6/2 HD model exhibits a
progressive HD-like phenotype that more closely corresponds
to human HD than previously believed [12]. There is a clear
longitudinal progression of disease along with neuronal death.
Recapitulation of the features of HD makes the R6/2 mice
highly suitable for pre-clinical therapeutic trials for HD [5,13].
Success using this model has led to a number of ongoing and
planned human clinical trials in HD patients [14]. As such, we
performed a dose ranging study administering high levels of
CoQ10 from two commercial sources in R6/2 mice to determine
any enhanced beneficial effects. A preliminary report of our
findings has been published [15].
2. Methods and materials
2.1. Animals
Male transgenic HD (R6/2) mice were obtained from an established colony
at the Bedford VA Medical Center and were bred with B6CBA females from
Jackson Laboratory (Bar Harbor, ME). The offspring were genotyped using a
PCR assay on tail DNA. Cohort homogeneity is essential in testing potential
therapies in murine models of disease. Minimizing measurement variability
increases the power to detect differences. We have standardized criteria to ensure
homogeneity of the experimental mice and the cohorts within the testing groups
[13]. Mice were randomized from 33 litters all within 4 days of the same age
from the same ‘f’ generation. Any mice that had altered base-paired banding
beyond 550 bp and less than 500 bp as identified from PCR analysis were
excluded from the study, since increased CAG repeats beyond 148–153 with
greater than 550 base pairs on PCR gels result in increased variability in disease
severity in the R6/2 mice [12]. Body weights were taken at 20 days and mice
were equally distributed according to weight and parentage within each cohort
(n=10). Mice under 8 g at 20 days were excluded from the experiments. Since
others and we have not observed gender differences in survival in the R6/2
transgenic HD mouse model, female mice were used in the experimental
paradigms. The mice were housed five in each cage under standard conditions
with ad libitum access to food and water. Mice were identified by a randomly
assigned code so that the studies were performed blind as to the genetic identity
of the mice. The mice were handled under the same conditions by one
investigator blinded (by the preclinical technical staff) to the genotype of the
mice and the type of diet administered. Each of the clinical/behavioral outcomeassessments was performed on the same day of the week at the same time of day.
We do not apply environmental enrichment in our facility, as this is considered a
therapeutic treatment that will confound the mouse trials. In our hands,
environmental enrichment results in greater heterogeneity of the clinical and
neuropathological phenotype, reducing the power to detect differences. All of
the experiments were performed in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and were approved by
both the Veterans Administration and Boston University Animal Care
Committees.
2.2. Therapeutic treatment
At 28 days of age, groups of 10 female R6/2 mice and littermate wild-type
control mice were placed on an unsupplemented diet and diets supplemented
with Chemco CoQ10 formulation at 1000, 5000, 10000, or 20000 mg/kg/day
(Chemco Industries Inc, Los Angeles, CA) (n=60) or with Tishcon CoQ10
formulation at 400, 1000, and 2000 mg/kg/day (Tishcon Corp., Westbury, NY)
(n=50). The Tishcon compound is a highly bioavailable formula of CoQ10 and
was provided as HydroQsorbR powder. The diets were made into pelleted mouse
chow (Research Diets, New Brunswick, NJ). Chow was analyzed every 2 weeks
to ensure that the levels of CoQ10 in each of the treatment chows remained the
same. In order to ensure that CoQ10 was present in the treated mice, CoQ10 doses
were confirmed in treated mice by HPLC analysis of serum (see methods
below). There was a dose-dependent increase in serum levels of CoQ10 in R6/2
treated mice consistent with the CoQ10 chow doses, confirming that the
mice were receiving CoQ10 (1000 mg/kg treated R6/2 mice: 0.133 μM/ml;
5000 mg/kg treated R6/2 mice: 0.149 μM/ml; 10000 mg/kg treated R6/2
mice: 0.152 μM/ml; 20000 mg/kg treated R6/2 mice: 0.191 μM/ml, Chemco
formulation). In addition, a positive therapy control group of R6/2 mice was
administered cystamine (225 mg/kg/day) in the drinking water. Cystamine is
a useful positive-control therapeutic since it has been consistently verified to
be efficacious in multiple different laboratories investigating HD [16–20].
2.3. Clinical assessment: motor performance, body weight, grip
strength, and survival
Motor performance and body weight was assessed weekly from 28 to 63
days of age and twice weekly from 63 to 90 days of age in the R6/2 and
littermate control mice. The mice were given two training sessions to acclimate
them to the rotarod apparatus (Columbus Instruments, Columbus, OH). During
testing the mice were placed on a rod rotated at a constant speed of 16 rpm. Each
mouse had three separate trials at 60 s each. The three results were averaged and
recorded. Fore- and hind-limb strength was measured weekly using a grip
strength meter (Columbus Instruments, Columbus, OH) [12]. Briefly, mice were
held by the scruff of their back and drawn along in a straight line along the
sensor to allow the mice to grasp the fore-limb pull bar assembly, recording the
force applied by the fore-limbs of the mouse in kilograms force. In a continued
sweep, the mouse was drawn along until the hind-limbs grasped and released the
hind-limb assembly, again recording the force applied by the hind-limbs of the
mouse. Fore-limb and hind-limb strength was measured by the same investigator
(KMS) 3 times and averaged during each weekly assessment. It is critically vital
that a single investigator perform the grip strength measurements due to
interrator differences in tensile strength. R6/2 mice were assessed for morbidity
and mortality twice daily, mid morning and late afternoon. Motor performance
and ability to feed were closely monitored and used as the basis for determining
when to euthanize the mice. The criterion for euthanization was the point in time
when the R6/2 mice were unable to right themselves within 30 s after being
placed on their back. A limited number of deaths occurred overnight and were
recorded the following morning. Two independent observers confirmed the
criterion for euthanization (RJF and KMS).
2.4. Neuropathological evaluation
At 28 days of age groups (n=10) of R6/2 and littermate wild-type control
mice were placed on either an unsupplemented diet or a diet supplemented with
the Chemco CoQ10 formulation at 5000 mg/kg. At 90 days of age, all animals
from each group were deeply anesthetized and then transcardially perfused with
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any perfusion artifact. It has been our experience that poor perfusion or variance
in perfusion pressure may result in significant differences in gross and
microscopic anatomy. Brains were cryoprotected and serially sectioned (50 μm).
Serial cut mouse tissue sections were stained for Nissl substance using cresyl
violet and immunostained for mutant Huntingtin. Sections were rinsed in tris-
buffered saline with Tween 20 (TBS-T) containing 10% normal goat serum for 1
h. Sections were then incubated overnight in TBS-Twith 0.1% sodium azide and
mouse anti-huntingtin (1:500, Chemicon, Temecula, CA). Sections were rinsed
three times in TBS-T, followed by a 2-3 h incubation in TBS-T containing a goat
anti-mouse peroxidase-conjugated secondary antibody to detect htt. Sections
were then rinsed three times in TBS-T. Antibody complexes were visualized
using diaminobenzidine. Preabsorbtion with excess target protein, or omission
of either primary or secondary antibody, was used to demonstrate antibody
specificity and background generated from the detection assay. Tissue sections
were examined using a Nikon Eclipse E800 microscope with a Spot RT digital
camera.
2.5. Stereology/quantitation
Serial-cut coronal tissue-sections beginning from the most rostral segment of
the neostriatum to the level of the anterior commissure (Interaural 5.34 mm/
Bregma 1.54 mm to Interaural 3.7 mm/Bregma −0.10 mm), were used for
huntingtin aggregate analysis. Unbiased stereological counts of huntingtin-
positive aggregates (≥1.0 μm) were obtained from the neostriatum in 10 mice
each from CoQ10-treated (5000 mg/kg Chemco formulation) and untreated R6/2
mice at 90 days using Neurolucida Stereo Investigator software (Microbright-
field, Colchester, VT). The total areas of the rostral neostriatum were defined in
serial sections in which counting frames were randomly sampled. The optical
dissector method was employed estimating the number of huntingtin-positive
aggregates. Striatal neuron areas were analyzed by microscopic videocapture
using a Windows-based image analysis system for area measurement (Optimas,
Bioscan Incorporated, Edmonds, WA). The software automatically identifies
and measures profiles. All computer identified cell profiles were manually
verified as neurons and exported to Microsoft Excel.
2.6. HPLC Analysis of CoQ9 and CoQ10
At 42 days of age, groups of 8 R6/2 mice were administered either 5000 mg/
kg/day CoQ10 (Chemco formulation) or 1000 mg/kg/day (Tishcon formulation)
or unsupplemented chow for 30 days, along with age-matched littermate wild-
type mice (n=32). Maximal serum concentrations are reached by 1 month and
plateau with continuous daily dosing [21]. Mice were euthanized at 73 days of
age by decapitation. Blood was collected and was allowed to clot at 4 °C and
centrifuged. Serum was removed, placed in eppendorf tubes and flash frozen in
liquid nitrogen at −80 °C. Brains were immediately removed and divided along
the longitudinal sagittal sulcus and further dissected in the coronal plane at the
optic chiasm. Each quartered brain area was immediately flash frozen at −80 °C.
From decapitation to freezing of brain tissue specimens took no more than 70 s
with a team of four investigators. Our experience has been that longer dissection
times result in increasing variability in the data that precludes significance.
Analysis of the samples began immediately after the dissection procedure. The
two rostral areas contained the frontal lobe and neostriatum. The left frontal lobe
of the brain was used for CoQ9, the predominant ubiquinone in mice, and CoQ10
measurements. Extraction took place in cold (4 °C) 2-propanol, sonicated for
3×10 s cycle and centrifuged for 10- min at 12K rpm at 4 °C. CoQ9 and CoQ10,
and analyzed using liquid chromatography with an ESA Coularray (LCEC
detection, cell potentials: mV 700, −1000, −1000, and 500 (ESA, Chelmsford,
MA). Samples were kept at 4 °C on an auto sampler. An ESA MD-150 column
was kept at 37 °C with a flow rate of 0.8 ml/min for 30 min, using a mobile phase
of 78% methanol, 20% 1-propanol, and 2% ammonium acetate pH 4.4. CoQ6
was used as an internal standard.
2.7. ATP analysis
The right frontal lobe of the brain from the HPLC cohorts was used for ATP
analysis. Four hundred μl of lysis buffer was added to each tissue sample,followed by homogenization with the Fisher PowerGen 125 tissue homogenizer.
The homogenized samples were centrifuged at 4 °C at 14000 RPM for 10 min.
Intracellular ATP levels were determined using a luciferase ATP assay kit
(Promega) according to the manufacture's instructions. The amount of ATP-
driven light produced was measured using a Luminoskan Ascent luminometer.
The amount of total cellular protein was determined with protein assay reagents
(Bio-Rad) using bovine serum albumin as a standard.
2.8. Urinalysis and brain levels for 8-hydroxy-2-deoxyguanosine
(OH8dG)
At 42 days of age, groups of 10 R6/2 mice were administered 5000 mg/kg/
day CoQ10 (Chemco formulation) or unsupplemented chow for 35 days, along
with age-matched littermate wild-type mice, in order to reach maximal serum
concentration levels. It has been our experience that the use of metabolic cages
to collect urine results in sample contamination. Alternatively, mice were
handled to urinate directly into eppendorf tubes. After 35 days of treatment,
approximately 100 μl of urine was collected, frozen on dry ice at −80 °C, and
transferred to a −80 °C freezer. Mice were euthanized at 77 days of age by
decapitation. Brains were immediately removed, quartered as above with
selective dissection of the striatum, and immediately flash frozen at −80 °C. An
HPLC method with electrochemical detection was used for analysis of OH8dG
levels in both urine and brain samples, as described in detail elsewhere [22,23].
The urinary levels represent nucleotide excision repair for the whole body
standardized to creatinine levels within each sample and are measured in ng/mg
creatinine. Creatinine levels were measured after OH8dG analysis on a 16
channel HPLC-EC Coularray (ESA, Chelmsford, MA) with UV detection at
236 nm, using a mobile phase A buffer (0.02 M NaH2PO4, 0.1% Methanol and
120 mg/l of tetrabutyl ammonium phosphate) and mobile phase B buffer (0.1 M
NaH2PO4, 0.1% Methanol, 20% Acetonitrile and 200 mg/l of tetrabutyl
ammonium phosphate) with a Tosohaas 4.6×25 cm TSK-GEL column and
autosampler set to 4 °C. The brain levels of OH8dG represent unrepaired damage
by base or nucleotide excision and are measured in pg/μg 2 deoxyguanosine
(2dG).
2.9. Statistics
The data are expressed as the mean±standard error of the mean. Statistical
comparisons of rotarod, weight data, grip strength, and neuropathological data
were compared by ANOVA or repeated measures of ANOVA and by non-paired
Student's t-test (Statview, CA). Survival data were analyzed by the Kaplan–
Meier survival curves.3. Results
Diets supplemented with Chemco CoQ10 formulation at
1000, 5000, 10000, or 20000 mg/kg/day and with Tishcon
CoQ10 formulation HydroQ-sorb at 400, 1000, and 2000 mg/
kg/day significantly improved the clinical phenotype of R6/2
mice in a dose dependent manner (Fig. 1A and B). Significant
prolongation of survival was observed in all doses using each
formulation. Using the Chemco formulation, the greatest pro-
longation in survival (21.3%) was observed at the 5000 mg/kg/
day dose, with less efficacy at higher doses (unsupplemented
R6/2 mice: 101.2±2.9 days; 1000 mg/kg/day CoQ10-treated
R6/2 mice: 117.0±6.0 days, P<0.001; 5000 mg/kg/day
CoQ10-treated R6/2 mice: 122.7 ± 7.4 days, P<0.001;
10000 mg/kg/day CoQ10-treated R6/2 mice: 112.8±6.1 days,
P<0.01; 20000mg/kg/dayCoQ10-treatedR6/2mice: 107.5±7.4
days, P<0.01). The Tishcon formulation also significantly
extended survival in the R6/2 mice, however, to a greater degree
(25.3%) and at a lower dose concentration of 1000 mg/kg/day
(unsupplemented R6/2 mice: 101.4±2.6 days; 400 mg/kg/day
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kg/day CoQ10-treated R6/2 mice: 127.0±7.4 days, P<0.001;
2000 mg/kg/day CoQ10-treated R6/2 mice: 123.6±7.2 days,
P<0.001). Each of these CoQ10 formulations resulted in
greater survival extension than a previously reported lower
dose of CoQ10 using a different formulation (Vitaline,
Ashland, OR) [3]. The positive control using oral cystamine
treatment in R6/2 mice resulted in an 18.0% extension in
survival and was consistent with previous work, providing
context to the current study [4] (unsupplemented R6/2 mice:
101.4±2.6 days; 225 mg/kg/day cystamine-treated R6/2 mice:
119.7±5.5 days).
There was a marked overall loss of body weight in the
unsupplemented R6/2 mice in comparison to wild type
littermate control mice (Fig. 1C). The effect of daily dietary
supplementation of high dose CoQ10 (Chemco formulation)
from each dosing paradigm on body weight was significantly
improved from 7 weeks of age through 13 weeks when
compared to the unsupplemented R6/2 mice (1000 mg/kg/day
CoQ10-treated R6/2 mice: F(89,826) 17.34, P<0.01; 5000 mg/kg/
day CoQ10-treated R6/2 mice: F(89,826) 19.22, P<0.01;
10000 mg/kg/day CoQ10-treated R6/2 mice: F(89,826) 21.16,
P<0.01; 20000 mg/kg/day CoQ10-treated R6/2 mice: 17.6±0.8
days, F(89,826) 24.08, P<0.01) (Fig. 1C). There were no
significant differences, however, in the amelioration of body
weight loss between CoQ10 doses. The weight curves of CoQ10-
treated mice closely paralleled one another. The effect on body
weight loss using the Tishcon CoQ10 formulation was not
different than the Chemco formulation. Administration of the
Tishcon CoQ10 resulted in reduced body weight loss in the R6/2
mice (1000 mg/kg dose F(49,634) 18.29, P<0.01). There was no
dose response to treatment. Interestingly, improvement of
weight loss profiles using both CoQ10 formulations in this
study was the same as that previously reported at a lower dose
using a different CoQ10 formulation (400 mg/kg/day; Vitaline,
Ashland, OR) [3].
An analysis of motor performance on the rotarod revealed
significant differences between R6/2 mice and wild-type
littermates (Fig. 1D). Using the Chemco formulation, CoQ10
treated R6/2 mice significantly improved in rotarod perfor-
mance starting at 5 weeks through 13 weeks of age, in
comparison to untreated R6/2 mice (1000 mg/kg/day CoQ10-
treated R6/2 mice: F(59,1023), 25.18, P<0.01; 5000 mg/kg/day
CoQ10-treated R6/2 mice: F(59,1023), 20.67, P<0.01; 10000 mg/
kg/day CoQ10-treated R6/2 mice: F(59,1023), 27.32, P<0.01;
20000 mg/kg/day CoQ10-treated R6/2 mice: F(59,1023), 26.54,
P<0.01) (Fig. 1D). The greatest improvement in rotarod
occurred at the 5000 mg/kg/day dose. The performance in
rotarod at 80 days for the 5000 mg/kg dose was over three-fold
greater than the unsupplemented R6/2 mice. The data for the
Tishcon formulation was no greater than that observed with the
Chemco formulation, however, with the greatest improvement
occurring at the 1000 mg/kg dose (F(49, 876) 29.84, P<0.01).
A grip strength meter was used to assess fore- and hind-limb
grip strength. Analysis is presented in Fig. 1E and F. There was
no significant difference between CoQ10-treated (Chemco
5000 mg/kg/day) and unsupplemented R6/2 mice in hind-limbgrip strength over the entire course of treatment. There was,
however, a significant difference in fore-limb strength after 11
weeks of age in the CoQ10-treated R6/2 mice (F(29,347)18.36,
P<0.01). Grip strength was not performed using the Tischon
formulation.
At 90 days, marked neuroprotection was observed. Serial cut
coronal tissue sections revealed gross brain atrophy, bilateral
ventricular hypertrophy, and flattening of the medial aspect of
the striatum in the unsupplemented R6/2 brains in serial
coronal-cut step sections, in comparison to wild type littermate
mice (Fig. 2). CoQ10 treatment (Chemco, 5000 g/kg/day)
ameliorated the gross brain atrophy in R6/2 mice, in comparison
to untreated mice at this time point (F(2,27) 17.49 , P<0.01).
Consistent with the attenuation of gross atrophy, the neuro-
protective effects of CoQ10 treatment significantly reduced
striatal neuron atrophy observed in the R6/2 mice (Wt litter-
mate control: 138.9±12.6 μm2; CoQ10-treated R6/2 mice:
116.8±17.1 μm2; unsupplemented R6/2 mice: 54.9±26.3 μm2;
F(2,30) 21.61, P<0.001) (Fig. 3). Since high dose administration
of therapeutic agents may result in liver toxicity and
subsequent damage, we performed a histopathological analysis
of liver in treated mice. No evidence of necrosis or inflam-
mation was observed in CoQ10-treated mice (data not shown).
Progressive accumulation of huntingtin-immunoreactive
aggregates has been shown to begin at postnatal day one in
R6/2 mice [12]. A number of compounds that have been
efficacious in the R6/2 transgenic mice, inclusive of lower dose
CoQ10, significantly reduce huntingtin-positive striatal aggre-
gates or ubiquitin-positive inclusions [5]. High dose CoQ10 was
no exception. In comparison to age-matched unsupplemented
R6/2 mice, CoQ10-treated R6/2 mice (Chemco, 5000 mg/kg/
day) demonstrated a marked reduction in huntingtin aggregate
(huntingtin aggregates in unsupplemented R6/2 mice:
5.78×106 ±1.39, 5000 mg/kg/day CoQ10-treated R6/2 mice:
4.89×106 ±1.07; F(2,32) 9.43, P<0.01) (Fig. 4). These findings,
however, were not significantly different than those reported
using a lower dose concentration of CoQ10 [3].
Two major functions of CoQ10 are as an electron carrier in
the mitochondrial respiratory chain and as a lipid-soluble
antioxidant. While in humans CoQ10 is the dominant species,
CoQ9 is the predominant ubiquinone in rodents, with as much
as 70% CoQ9 making up the total [24]. It was unclear at the
onset of these preclinical trials whether increased levels of
CoQ10 would have an effect upon CoQ9 levels in the R6/2
mice. We show a comparison of both CoQ9 and CoQ10 in
both serum and brain of unsupplemented wild type littermate
and R6/2 mice and in R6/2 mice at their optimal survival
dosing concentrations of 5000 mg/kg/day and 1000 mg/kg/
day using the CoQ10 Chemco and Tishcon formulations,
respectively, on day 73 after 30 days treatment (Fig. 5). As
measured by HPLC, baseline serum levels of CoQ10 in wild
type littermate and R6/2 mice were 0.004 μM/ml and
0.002 μM/ml, respectively (Fig. 5A). The Chemco and
Tishcon CoQ10 formulations increased CoQ10 serum levels
by 70 and 300 fold, respectively, in R6/2 mice (Fig. 5A)
(Littermate wild type mice: 0.004±0.0004 μM/ml; untreated
R6/2 mice: 0.002±0.0005 μM/ml; Chemco CoQ10-treated R6/
Fig. 1. Survival, body weight, rotarod, and grip strength in untreated and coenzyme Q10 (CoQ10) treated R6/2 transgenic mice. Cohorts of R6/2 mice (n=10) were
treated from day 28 with oral administration of CoQ10 (1000, 5000, 10,000, and 20,000 mg/kg/day, Chemco). Kaplan–Meier probability of survival analyses of CoQ10
treatment and untreated R6/2 mice are presented in A. Survival was significantly extended using all CoQ10 doses in R6/2 mice in comparison to untreated R6/2 mice,
with greatest efficacy in the 5 gm/kg/day dose by 21.3%, P<0.001 (untreated R6/2 mice: 101.2±2.9 days; CoQ10 1000 mg/kg R6/2 mice: 117.0±6.0 days; CoQ10
5000 mg/kg R6/2 mice: 121.3±7.4 days; CoQ10 10000 mg/kg R6/2 mice: 112.8±6.1 days; CoQ10 20000 mg/kg R6/2 mice: 107.5±7.4 days). The Tishcon
formulation provided greater survival extension (25.3%, P<0.001) at lower dose (untreated R6/2 mice: 101.4±2.6 days; 400 mg/kg/day CoQ10-treated R6/2 mice:
114.4±5.5 days; 1000 mg/kg/day CoQ10-treated R6/2 mice: 125.8±7.4 days; 2000 mg/kg/day CoQ10-treated R6/2 mice: 123.6±7.2 days) (B). The body weight,
rotarod, and grip strength outcome measures are shown using the Chemco formulation only. Effects of CoQ10 treatment on the body weight in R6/2 mice are shown in
C. Significant body weight differences between untreated and CoQ10 treated R6/2 mice occurred in all doses from 7 weeks through end stage disease. Motor
performance using rotarod was improved using all doses starting at 5 weeks through 13 weeks as shown in D. Grip strength was significant in fore-limb analysis (E)
after 79 days (asterisk), with no significant differences in hind-limb analysis (F). Asterisk (⁎) denotes significance as compared untreated R6/2 mice.
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CoQ10-treated R6/2 mice: 0.679±0.054 μM/ml, F(2,32)7.16,
P<0.0001), while not significantly increasing serum CoQ9
levels (Fig. 5B) (Littermate wild type mice: 0.075±0.006 μM/
ml untreated R6/2 mice: 0.066±0.009 μM/ml; Chemco
CoQ10-treated R6/2 mice: 0.082±0.008 μM/ml, P<0.10;Tishcon CoQ10-treated R6/2 mice: 0.084±0.011 μM/ml,
P<0.08).
Brain levels of CoQ10 were significantly lower in R6/2
mice by 20%, in comparison to wild type littermate mice
(Fig. 5C). Administration of the Chemco and Tishcon CoQ10
formulations significantly increased brain CoQ10 levels in R6/
Fig. 2. Gross brain neuroprotection with coenzyme Q10 (CoQ10) treatment. Photomicrographs of coronal serial step sections from the rostral neostriatum through the
level of the anterior commissure in a wild-type littermate mouse (A1–A4), CoQ10 treated (Chemco, 5 mg/kg/day) R6/2 HD transgenic mouse (B1–B4), and untreated
R6/2 HD transgenic mouse (C1–C4) at 90 days. There is gross atrophy of the brain and ventricular enlargement in the untreated R6/2 mouse (C1–C4) compared with
the wild type littermate control (A1–A4). In contrast, the CoQ10 treated R6/2 (B1–B4) shows reduced gross brain atrophy and reduced ventricular enlargement
compared to the untreated R6/2 mouse (C1–C4). Scale bar in A1 equals 2 mm.
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untreated R6/2 mice (Fig. 5C) (Littermate wild type mice:
5.25±0.21 ng/mg; untreated R6/2 mice: 4.20±0.39 ng/mg;
Chemco CoQ10-treated R6/2 mice: 5.14±0.26 ng/mg,
F(3,32)19.29, P<0.01; Tishcon CoQ10-treated R6/2 mice:
6.39±0.21 ng/mg, F(3,32)15.10, P<0.001). Brain levels of
CoQ9 were also significantly lower in R6/2 by 19.7%, in
comparison to wild type littermate mice (Fig. 5D). Both the
Chemco and Tishcon formulations significantly increased
CoQ9 brain levels by 38.3% and 40.1%, respectively
(Littermate wild type mice: 10.13±0.62 ng/mg; untreated
R6/2 mice: 8.14±0.74 ng/mg; Chemco CoQ10-treated R6/2
mice: 11.26±0.55 ng/mg, F(3,32) 14.53, P<0.01; Tishcon
CoQ10-treated R6/2 mice: 11.40±0.61 ng/mg, F(3,32)12.78,
P<0.01). These findings are consistent with the neuroprotec-
tive effects of CoQ10 in R6/2 mice.
Using HPLC analysis, we previously showed a significant
decrease in both creatine and ATP levels in the R6/2 mice, in
comparison to littermate control mice, suggesting that mito-
chondrial dysfunction was present in the R6/2 HD model [4].
We now confirm and extend the ATP results using a luciferase
method. There was a 35.6% reduction in ATP levels in R6/2
mice, in comparison to littermate wild-type mice (Fig. 6). Both
Chemco (5000 mg/kg/day) and Tishcon (1000 mg/kg) CoQ10
supplementation significantly increased ATP levels in brain
tissue samples from R6/2 mice, in comparison to unsupple-mented R6/2 mice, to those levels detected in normal littermate
control mice (littermate control: 9.11±0.22 pmol/mg; untreated
R6/2 mice: 5.87±0.41 pmol/mg; Chemco CoQ10-treated R6/2
mice: 9.61±0.32 pmol/mg, F(3,32) 15.72, P<0.01; Tishcon
CoQ10-treated R6/2 mice: 9.68±0.39 pmol/mg, F(3,32) 19.01,
P<0.01).
Consistent with previous reports, both brain and urinary
OH8dG levels in R6/2 mice were significantly increased in
comparison to wild type littermate mice, suggesting that
oxidative stress plays a role in the pathogenesis of neuronal
degeneration in the R6/2 transgenic mouse model of HD [23].
After clinical disease onset (42d), R6/2 mice were treated with
CoQ10 (Chemco 5000 mg/kg/day) for 35 days, until 11 weeks.
OH8dG levels in CoQ10-treated R6/2 mice were significantly
reduced, as compared to untreated R6/2 mice in brain (wild type
littermate mice: 12.5±3.7 pg/μg 2dG; untreated R6/2 mice:
48.6±9.6 pg/μg 2dG; CoQ10-treated R6/2 mice: 25.4±5.8 pg/
μg 2dG, F(2,58) 16.29, P<0.01) and urine (wild type littermate
mice: 6.6 ± 2.3 ng/mg creatinine; untreated R6/2 mice:
23.6 ± 5.4 ng/mg creatinine; CoQ10-treated R6/2 mice:
7.6±3.1 ng/mg creatinine, F(2,58) 19.34, P<0.01) (Fig. 7).
The urinary levels measure the aggregate effect of damage and
nucleotide excision repair for the whole body, while the brain
levels measure the amount of damage that has not been repaired
by either base or nucleotide excision. The OH8dG levels in wild
type and R6/2 mice are comparable to those previously reported
Fig. 4. Huntingtin (Htt) immunoreactivity in coenzyme Q10 (CoQ10) treated R6/
2 mice. Htt immunostained tissue sections from the striatum at 90 days in
untreated (A) and 1 gm/kg CoQ10 (B) and 5000 mg/kg treated (C) (Chemco
formulation) R6/2 transgenic mice. The number and size of htt aggregates, as
well as intensity of immunostaining, is significantly reduced in both CoQ10
doses with a dose response reduction in htt aggregates greatest in the 5000 mg/
kg dose. Scale bar in A equals 100 μm.
Fig. 3. Neuronal protection after coenzyme Q10 (CoQ10) administration. Nissl-
stained tissue sections from the dorsomedial aspect of the neostriatum at 90 days
in wild-type littermate control (A), untreated R6/2 (B), and a CoQ10 treated R6/2
mice (C) (Chemco, 5000 mg/kg/day), show marked neuronal atrophy in the
untreated R6/2 mouse (B) with significantly less neuronal atrophy in the CoQ10
treated mouse (C), as compared with the control WTmice (Wt littermate control:
138.9±12.6 μm2; CoQ10-treated R6/2 mice: 116.8±17.1 μm
2; unsupplemented
R6/2 mice: 54.9±26.3 μm2; F(2,30) 21.61, P<0.001). Greater cell packing
density occurs in the untreated R6/2 mice as a consequence of tissue loss and
neuronal atrophy (B). Scale bar in A equals 100 μm.
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Fig. 6. ATP levels after coenzyme Q10 (CoQ10) administration. Using a
luciferase technique, there was a significant decrease (35.6%) in ATP levels in
the R6/2 mice, in comparison to littermate control mice, suggesting
mitochondrial dysfunction in the R6/2 HD model. In contrast, there was a
significant increase in ATP levels in brain tissue samples from both the Chemco
and Tishcon CoQ10-treated R6/2 mice, in comparison to unsupplemented R6/2
mice (P<0.01). The ATP levels found in CoQ10 supplemented R6/2 mice were
not significantly different from littermate control mice (littermate control:
9.11±0.22 pmol/mg; unsupplemented R6/2 mice: 5.87±0.41 pmol/mg; CoQ10
supplemented R6/2 mice: 9.61±0.32 pmol/mg; Tishcon CoQ10-treated R6/2
mice: 9.68±0.39 pmol/mg). Wild Type littermate▪, untreated R6/2□, Chemco
CoQ10treated , Tishcon CoQ10treated . Asterisk (*) denotes significance as
compared untreated R6/2 mice.
Fig. 5. Serum and brain levels of coenzyme Q10 (CoQ10) and coenzyme Q9
(CoQ9) in R6/2 mice. As measured by HPLC, serum levels of CoQ10 in bothWT
and R6/2 mice were 0.004 and 0.002 μM/ml, respectively (A). Doses of the
Chemco (5000 mg/kg) and the Tishcon (1000 mg/kg) formulations increased
CoQ10 serum levels by 70 and 300 fold, respectively (A). CoQ9 serum levels
were not significantly increased in comparison to untreated R6/2 mice (B). Brain
levels of CoQ10 were significantly reduced in R6/2 mice, in comparison to wild
type (WT) littermate control mice (C). Administration of the Chemco and
Tishcon CoQ10 compounds significantly increased CoQ10 brain levels in R6/2
mice by 22.4% and 52.1% (P<0.01), respectively, in comparison to untreated
R6/2 mice (C). Brain levels of CoQ9 were significantly reduced in R6/2 mice
(19.7%, P<0.01), in comparison toWTmice (D). Both the Chemco and Tishcon
compounds significantly increased CoQ9 brain levels by 38.3% and 40.1%,
respectively, consistent with the neuroprotective effects of CoQ10 supplemen-
tation in the R6/2 mice. Wild Type littermate ▪, untreated R6/2 □, Chemco
CoQ10treated , Tishcon CoQ10treated . Asterisk (*) denotes significance as
compared untreated R6/2 mice.
Fig. 7. OH8dG urine and brain levels after coenzyme Q10 (CoQ10)
administration. There were marked increases in OH8dG urine (A) and brain
(B) levels in R6/2 mice, in comparison to littermate wild-type control mice, with
a significant reduction to normal levels in the CoQ10 treated R6/2 mice. Wild
Type littermate ▪, untreated R6/2 □, Chemco CoQ10treated . Asterisk (*)
denotes significance as compared untreated R6/2 mice.
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4. Discussion
We show that that high-dose administration of CoQ10 exerts
a greater therapeutic benefit in a dose-dependent manner in R6/
2 mice than previously reported at lower CoQ10 doses and thatsignificant, yet variable, dose-dependent efficacy may result
from different commercial sources. High-dose CoQ10 signifi-
cantly improved both the behavioral and neuropathological
phenotype of R6/2 mice, delaying the development of weight
loss, motor deficits, grip strength, gross brain atrophy, striatal
neuron atrophy, and huntingtin aggregates in R6/2 mice. The
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lower dose. CoQ10 also ameliorated biomarkers of bioenergetic
dysfunction and oxidative stress found in R6/2 mice. This
ergogen dramatically improved serum CoQ10 and brain CoQ10
and CoQ9 levels, while increasing brain ATP levels in treated
R6/2 mice to normal wild type littermate control concentrations,
cohering to the observed neuroprotective effects. In addition,
CoQ10 decreased elevated OH
8dG levels in R6/2 mice, a
finding consistent with reduced oxidative injury.
High doses of orally ingested therapeutic agents, both drug
and natural compounds, may irritate the gut and alter gut flora,
resulting in gastritis, increased elimination of food products, and
reduced absorption. Gastrointestinal upset is one of the most
common adverse events in both human and animal therapeutic
trials and may occur subclinically without obvious evidence.
This may have been the cause of reduced efficacy at the highest
CoQ10 doses in this mouse trial. Dose escalation, starting at
lower more tolerable doses while advancing to the higher doses,
may have resulted in greater improvement in outcome measures
in the R6/2 HD mice than that reported herein.
CoQ10 is a lipid-soluble benzoquinone derivative that resides
in the inner mitochondrial membrane and is an essential
coactivator in shuttling electrons from complexes I and II to
complex III of the electron transport chain during oxidative
phosphorylation. CoQ10 plays a vital role in ATP production
and serves as an anti-oxidant in both mitochondrial and lipid
membranes [21,25,26], directly scavenging free radicals in the
inner mitochondrial membrane by mediating uncoupling
through superoxide production [27,28]. CoQ10 has been used
to treat a number of human medical conditions, the most
prominent of which are mitochondrial disorders, and is most
efficacious where there is an inherited deficiency of CoQ10 [29–
34]. CoQ10 is effective in slowing the progression of
neurological disease [34,35]. There is also substantial evidence
that CoQ10 is efficacious in mouse models of HD and may have
benefit in HD patients [3,6,36–38]. Oral administration of
CoQ10 significantly improved both the clinical and neuropath-
ological phenotype in R6/2 mice using a different formulation at
a lower dose [3]. As such, a recent multicenter clinical trial
(CARE-HD) of CoQ10 (600 mg/day) in HD patients showed a
trend towards slowing in total functional capacity decline over
30 months, significance in slowing decline on the independence
scale, and a significant beneficial effect on measures of
cognitive function, including Stroop color naming and word
reading tasks [6]. Since the single target dose, however, did not
provide significance in the specified primary outcome of the
trial, it remains unclear whether a higher CoQ10 dose would
provide greater efficacy in HD patients.
An important advance in developing drug compounds for
clinical trials in HD patients has been the introduction of genetic
mouse models of HD. Of the available HD murine models, the
R6/2 transgenic mouse has been the most widely used in
preclinical trials testing potential therapies [5]. The efficiency
and clear experimental endpoints of the R6/2 mice remain a
major advantage over most HD mouse models in preclinical
testing, with recent evidence suggesting that the behavioral and
neuropathological changes more accurately replicate thoseobserved in human HD [12]. Phenotype homogeneity is
essential in testing potential therapies in these mice, minimizing
measurement variability and increasing the power to detect
differences between the test groups [13]. For example,
variability in phenotype severity in R6/2 mice may be
dependent on CAG repeat size. There is evidence that increased
CAG repeats beyond that originally reported in the R6/2 mice
result in marked heterogeneity of the R6/2 phenotype, with the
potential of reducing their utility in therapeutic trials [12]. In
addition, the practice of using environmental enrichment in
some laboratories can be considered as a therapeutic treatment
that may confound mouse trials. Enrichment results in greater
heterogeneity of the clinical and neuropathological phenotype,
lowering the power to detect differences.
Methodological variances in testing paradigms can also result
in differing expression of outcome responses that may produce
differences in data interpretation, with the potential to obscure
therapeutic efficacy. In N171-82Q transgenic HD mice,
significant survival extension was not found combining CoQ10
and remacemide treatment, with only transient improvement of
motor performance [37]. Others, however, have showed
significant efficacy in survival, in addition to other behavioral
analyses in N171-82Q mice [3]. Similar divergent results in the
efficacy of minocycline in R6/2 mice have been reported and are
most likely the result of different methods of treatment and
measuring outcomes [39,40]. In contrast, there are classes of
agents, such as transglutaminase inhibitors (cystamine) and
histone deacetylase inhibitors (butyrates) where the results of
efficacy in outcome measures are agreed upon across laborato-
ries [16–20,41–43]. The latter may be due to the proximity of
these agents to the pathophysiological mechanisms associated
with HD. Consistent with previous studies, and that mitochon-
drial dysfunction may play a proximal role in the pathogenesis of
HD, we show a robust effect of high-dose CoQ10 in R6/2 mice
with greater than 25% extension in survival.
While survival is an important surrogate indicator for
neuroprotection, it may not be possible to use this outcome
measure in some laboratories. Longitudinal biomarkers of
disease that measure pathological phenotype can validate
therapeutic efficacy. We have identified two such biomarkers
in the R6/2 mice, ATP levels characterizing the bioenergetic
defect and OH8dG levels as a marker of oxidative stress. We
have previously showed that creatine and ATP levels are
reduced in R6/2 mice [4]. We confirm this finding and
additionally demonstrate that ATP levels are recovered by
CoQ10 treatment. A useful biomarker of oxidative damage to
DNA is OH8dG. Significant increases occur in OH8dG levels
in nuclear DNA in the caudate nucleus in post-mortem tissue
from HD patients [44], as well as in mitochondrial DNA from
parietal cortex [45]. OH8dG levels are elevated in urine,
serum, and brain samples from R6/2 mice [23]. We show that
CoQ10 administration reduces OH
8dG to normal levels,
consistent with a neuroprotective effect. Of great interest is
a recent study demonstrating that serum OH8dG levels are
elevated in HD patients and that creatine treatment, a similar
acting ergogen, ameliorated OH8dG increases [46]. This is the
first such instance of parallel efficacy, using a common
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agent in HD mice and patients.
Successful preclinical trials demonstrating improved pheno-
type in HD transgenic mice have yet to be validated in HD
patients. This may be the consequence of insufficient fully-
powered clinical trials in humans to permit a comparison of
therapeutic efficacy between mouse and man. Alternatively,
optimal therapeutic dosing may be underestimated, as perhaps
was the case for CoQ10 supplementation in HD patients in the
recent CARE-HD trial [6]. Human Equivalent Dose extrapola-
tion measurements derived from body surface area criteria in
animals [47] may not accurately predict the maximum-
recommended safe dose in neurological disorders. This is
evident in human trials where human equivalent dosing of
bioenergetic agents comparable to that given to mice, while
considered safe and tolerable, have not demonstrated significant
efficacy in patients [48–50]. There is, however, a growing body
of evidence suggesting that the phenotypes from mouse models
of neurological diseases closely correlate with human diseases
and may validate known CNS drug targets in a therapeutically
relevant manner [5,14,51]. The strengths of the HD mouse
models are in their utility to provide parallel pathophysiological
targets that are present in HD patients, in their potential as
sensitive predictors for therapeutic intervention, and their
promise in the development of novel drug agents. While drug
trials in mice confirm therapeutic direction, the challenge is in
determining what dose might be of value in patients since the
pharmacokinetics of mice and man is dissimilar.
The present results suggest that higher dose CoQ10, consistent
with that shown in safety and tolerability trials of other age-
related neurodegenerative disorders [8,9], may provide greater
efficacy in HD patients. Administration of CoQ10 at high doses,
however, should be closely monitored in test patients, largely
because the safety of high-dose administration over a long period
of time has yet to be established. It is likely that a bioenergetic
agent, such as CoQ10, will represent one of the cornerstone
defenses in ameliorating the progression of HD. The present
study provides a rationale for high-dose CoQ10 as an immediate
candidate for clinical trials in HD patients.
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